| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802743501015 | 274350101 | LYOPRAZ GR.CAP 20MG/CAP ΒΤ x 14 (σε φιαλίδιο) (σε φιαλίδιο) | 03.05 | 3.20 | 4.41 |
| 05/2018 | 2802743501022 | 274350102 | LYOPRAZ GR.CAP 20MG/CAP BT x 28 (σε φιαλίδιο) (σε φιαλίδιο) | 6.12 | 6.42 | 8.85 |
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
Blurred vision, confusion, drowsiness, dry mouthflushingheadache, nausea, rapid heartbeat, sweating
90%
1-1.5 hours
Esomeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system. Esomeprazole is excreted as metabolites primarily in urine but also in feces. Less than 1% of parent drug is excreted in the urine.
* 16 L [healthy volunteers]